H-alpha Kinematics of the SINGS Nearby Galaxies Survey. II

This is the second part of an H-alpha kinematics follow-up survey of the Spitzer Infrared Nearby Galaxies Survey (SINGS) sample. The aim of this program is to shed new light on the role of baryons and their kinematics and on the dark/luminous matter relation in the star forming regions of galaxies, in relation with studies at other wavelengths. The data for 37 galaxies are presented. The observations were made using Fabry-Perot interferometry with the photon-counting camera FaNTOmM on 4 different telescopes, namely the Canada-France-Hawaii 3.6m, the ESO La Silla 3.6m, the William Herschel 4.2m, and the Observatoire du mont Megantic 1.6m telescopes. The velocity fields are computed using custom IDL routines designed for an optimal use of the data. The kinematical parameters and rotation curves are derived using the GIPSY software. It is shown that non-circular motions associated with galactic bars affect the kinematical parameters fitting and the velocity gradient of the rotation curves. This leads to incorrect determinations of the baryonic and dark matter distributions in the mass models derived from those rotation curves.Comment: 18 pages, 5 figures, 4 tables. Accepted for publication in MNRAS. All high-res. figures are available at http://www.astro.umontreal.ca/fantomm/singsII

The Relationship Between Gas Content and Star Formation in Molecule-Rich Spiral Galaxies

We investigate the relationship between HI, H_2, and the star formation rate (SFR) using azimuthally averaged data for seven CO-bright spiral galaxies. Contrary to some earlier studies based on global fluxes, we find that the SFR surface density exhibits a much stronger correlation with the H_2 than with the HI, as the HI surface density saturates at a value of $\sim$10 Msol pc^{-2} or even declines at large SFR surface densities. Hence the good correlation between the SFR surface density and the total (HI+H_2) gas surface density is driven by the molecular component in these galaxies. We find no clear evidence for a link between the gravitational instability parameter for the gas disk (Q_g) and the SFR, and suggest that Q_g be considered a measure of the gas fraction. This implies that for a state of marginal gravitational stability to exist in galaxies with low gas fractions, it must be due to instability of the stellar disk. In regions where we have both HI and CO measurements, the ratio of HI to H_2 surface density scales with radius R as roughly R^{1.5}, and we suggest that the balance between HI and H_2 is determined primarily by the midplane interstellar pressure. These results favor a "law" of star formation in quiescent disks in which the ambient pressure and metallicity control the formation of molecular clouds from HI, with star formation then occurring at a roughly constant rate per unit H_2 mass. (abstract abridged)Comment: To appear in ApJ. 28 pages with 16 figures (emulateapj5). Full resolution figures available at http://www.atnf.csiro.au/people/twong/preprints

Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening

<p>Abstract</p> <p>Background</p> <p>Rheumatoid arthritis (RA) is an autoimmune disease with unknown etiology. Anticitrullinated protein autoantibody has been documented as a highly specific autoantibody associated with RA. Protein arginine deiminase type 4 (PAD4) is the enzyme responsible for catalyzing the conversion of peptidylarginine into peptidylcitrulline. PAD4 is a new therapeutic target for RA treatment. In order to search for inhibitors of PAD4, structure-based virtual screening was performed using LIDAEUS (Ligand discovery at Edinburgh university). Potential inhibitors were screened experimentally by inhibition assays.</p> <p>Results</p> <p>Twenty two of the top-ranked water-soluble compounds were selected for inhibitory screening against PAD4. Three compounds showed significant inhibition of PAD4 and their IC₅₀values were investigated. The structures of the three compounds show no resemblance with previously discovered PAD4 inhibitors, nor with existing drugs for RA treatment.</p> <p>Conclusion</p> <p>Three compounds were discovered as potential inhibitors of PAD4 by virtual screening. The compounds are commercially available and can be used as scaffolds to design more potent inhibitors against PAD4.</p

Ability of T1 lipase to degrade amorphous P(3HB): structural and functional study

An enzyme with broad substrate specificity would be an asset for industrial application. T1 lipase apparently has the same active site residues as polyhydroxyalkanoates (PHA) depolymerase. Sequences of both enzymes were studied and compared, and a conserved lipase box pentapeptide region around the nucleophilic serine was detected. The alignment of 3-D structures for both enzymes showed their active site residues were well aligned with an RMSD value of 1.981 Å despite their sequence similarity of only 53.8%. Docking of T1 lipase with P(3HB) gave forth high binding energy of 5.4 kcal/mol, with the distance of 4.05 Å between serine hydroxyl (OH) group of TI lipase to the carbonyl carbon of the substrate, similar to the native PhaZ7 Pl . This suggests the possible ability of T1 lipase to bind P(3HB) in its active site. The ability of T1 lipase in degrading amorphous P(3HB) was investigated on 0.2% (w/v) P(3HB) plate. Halo zone was observed around the colony containing the enzyme which confirms that T1 lipase is indeed able to degrade amorphous P(3HB). Results obtained in this study highlight the fact that T1 lipase is a versatile hydrolase enzyme which does not only record triglyceride degradation activity but amorphous P(3HB) degradation activity as well

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population

Viability of magnetic denture retainers: A 3-year case report

Quintessence International327517-52

Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure

Aim: To compare the effect of brimonidine and timolol in reducing visual field loss in patients with acute primary angle closure (APAC). Methods: In addition to standard acute medical treatment, patients presenting with APAC were randomised to either brimonidine 0.2% or timolol 0.5% upon diagnosis, then twice daily for 4 weeks. After laser peripheral iridotomy (LPI), subjects underwent three baseline perimetry tests during the first week, and then at weeks 4, 8, 12, and 16. Pointwise linear regression analysis was applied to the field series of each of these subjects starting with the third test (total of five tests per subject). Progression was defined as a significant regression slope (p<0.05) showing 1 dB per year or more of sensitivity loss at the same test location in the series. Patients were also compared for prevalence of abnormal fields at 16 weeks, which was defined as an abnormal glaucoma hemifield test result and/or corrected pattern standard deviation outside the 95% confidence limits. Results: 59 subjects (31 in the brimonidine group; 28 in the timolol group) completed the study. There were 47 females (79.7%), the majority of subjects (94.9%) were Chinese and the mean age was 59.2 (SD 7.2) years. There were no significant differences between the two groups with respect to demographic features, presenting intraocular pressure (IOP), duration of symptoms, time from presentation to LPI, or mean IOP at each study visit. Over the 16 week study period, despite adequate statistical power, no difference was found between groups in terms of the number of patients with progressing locations, the mean number of progressing locations per subject, or the mean slope of the progressing locations. Nine (29%) subjects in the brimonidine group and 10 (35.7%) in the timolol group were found to have significant visual field defects at 16 weeks (p = 0.58). 15 out of these 19 subjects (78.9%) already had these visual field defects in the first week. Conclusions: In the first 16 weeks after APAC, there was no difference in the prevalence of visual field defects or rate of visual field progression between brimonidine and timolol treated groups